Skip to main content
New GLP-1 protocol guide just published Read →
Editor reviewing manuscript pages with red pen annotations at a sunlit desk
§ 07 Editorial

News from the
peptide desk.

Regulatory changes, research summaries, and market context for peptide therapy — tightened into an editorial feed instead of a dense archive wall.

§ 01 Lead Story
Lead story
— Peptidely Editorial Team
Regulatory Updates Mar 15, 2025

Semaglutide Shortage Ends: What It Means for Compounded GLP-1 Access

The FDA declared the semaglutide shortage resolved in early 2025, triggering enforcement action against compounding pharmacies. Here's what changed and what patients should know.

Read the analysis
§ 02 The Archive

Recent reporting.

Shorter summaries and a cleaner metadata row to make the archive easy to scan.

Regulatory Updates Feb 1, 2025

BPC-157 in 2025: What the FDA Prohibition Means and What Remains

The 2023 FDA prohibition of BPC-157 from 503A compounding changed the landscape for one of the most popular research peptides. Here's an honest assessment of where things stand.

#BPC-157 #Regulatory
Read

Keep exploring

If the blog surfaces a topic you want to understand in more depth, jump into the structured reference pages.

Therapy Guides →
Long-form explainers for regulation, dosing context, compounding, and safety.
Research Hub →
Landmark studies, evidence tiers, and the most researched compounds.